A Comprehensive Review of Vaccine Development: From Traditional Platforms to Messenger RNA (mRNA) Technologies

The trend of vaccine development over the last few years is that the traditional platform has been abandoned and moved towards newer modalities, and the current COVID-19 pandemic has accelerated this shift. Classical approaches (such as inactivated, live attenuated, and recombinant) can be shown to have reduced the burden of infectious diseases; however, they are also limited by their inability to scale production and prolonged development, as well as cold-chain limitations. The lacks became apparent through the pandemic and drove the demand for more agile, adaptive technology that COVID-19 has highlighted. The current review questions the goal of streamlining the immunization approaches in the face of emerging pathogens through a structured narrative comparison of immunogenicity, safety, efficacy, and platform stability of modern vaccination platforms within a narrative review framework. This analysis is anchored by a narrative synthesis of immunological, regulatory, and clinical literature between 2018 and 2025. Messenger RNA (mRNA)-based vaccines have demonstrated strong immunogenicity and practical efficacy in the real world, as well as varying safety profiles across platforms and the potential of new modalities that will be developed both to treat infectious diseases and to be applied in other contexts. The discussion also dwells upon the flexibility of regulation, unequal distribution, and surveillance-based pharmacovigilance. This review can be used to compile a thoroughly comparative view of modern vaccines, based on bringing together mechanistic insights and implementation barriers, which can guide future innovation and policy reconciliation and global resilience. It makes inferences in support of the more progressive, equity-based paradigm of pandemic preparedness and immunization strategy in the 21st century. This review highlights how mRNA technology has transformed the landscape of vaccinology, offering a foundation for faster, safer, and more equitable global immunization strategies in the post-pandemic era.